Your browser doesn't support javascript.
loading
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.
Claireaux, Mathieu; Caniels, Tom G; de Gast, Marlon; Han, Julianna; Guerra, Denise; Kerster, Gius; van Schaik, Barbera D C; Jongejan, Aldo; Schriek, Angela I; Grobben, Marloes; Brouwer, Philip J M; van der Straten, Karlijn; Aldon, Yoann; Capella-Pujol, Joan; Snitselaar, Jonne L; Olijhoek, Wouter; Aartse, Aafke; Brinkkemper, Mitch; Bontjer, Ilja; Burger, Judith A; Poniman, Meliawati; Bijl, Tom P L; Torres, Jonathan L; Copps, Jeffrey; Martin, Isabel Cuella; de Taeye, Steven W; de Bree, Godelieve J; Ward, Andrew B; Sliepen, Kwinten; van Kampen, Antoine H C; Moerland, Perry D; Sanders, Rogier W; van Gils, Marit J.
Afiliação
  • Claireaux M; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Caniels TG; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • de Gast M; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Han J; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Guerra D; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Kerster G; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • van Schaik BDC; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Jongejan A; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Schriek AI; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Grobben M; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Brouwer PJM; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • van der Straten K; Bioinformatics Laboratory, Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam Institute for Public Health, Amsterdam, the Netherlands.
  • Aldon Y; Bioinformatics Laboratory, Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam Institute for Public Health, Amsterdam, the Netherlands.
  • Capella-Pujol J; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Snitselaar JL; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Olijhoek W; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Aartse A; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Brinkkemper M; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Bontjer I; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Burger JA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Poniman M; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Bijl TPL; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Torres JL; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Copps J; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Martin IC; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • de Taeye SW; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • de Bree GJ; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Ward AB; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Sliepen K; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • van Kampen AHC; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • Moerland PD; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
  • Sanders RW; Amsterdam UMC, University of Amsterdam, Department of Medical Microbiology and Infection prevention, Laboratory of Experimental Virology, Amsterdam, the Netherlands.
  • van Gils MJ; Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, the Netherlands.
Nat Commun ; 13(1): 4539, 2022 08 04.
Article em En | MEDLINE | ID: mdl-35927266
Delineating the origins and properties of antibodies elicited by SARS-CoV-2 infection and vaccination is critical for understanding their benefits and potential shortcomings. Therefore, we investigate the SARS-CoV-2 spike (S)-reactive B cell repertoire in unexposed individuals by flow cytometry and single-cell sequencing. We show that ∼82% of SARS-CoV-2 S-reactive B cells harbor a naive phenotype, which represents an unusually high fraction of total human naive B cells (∼0.1%). Approximately 10% of these naive S-reactive B cells share an IGHV1-69/IGKV3-11 B cell receptor pairing, an enrichment of 18-fold compared to the complete naive repertoire. Following SARS-CoV-2 infection, we report an average 37-fold enrichment of IGHV1-69/IGKV3-11 B cell receptor pairing in the S-reactive memory B cells compared to the unselected memory repertoire. This class of B cells targets a previously undefined non-neutralizing epitope on the S2 subunit that becomes exposed on S proteins used in approved vaccines when they transition away from the native pre-fusion state because of instability. These findings can help guide the improvement of SARS-CoV-2 vaccines.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article